SQUAREX

squarex-logo

Squarex is a clinical-stage pharmaceutical company developing a drug and topical application to prevent infections. This application develops a topical formulation of the immunomodulator squaric acid dibutyl ester for the prevention of recurrent cold sores and other infections caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2. The company was founded in 2012 and is headquartered in Saint Paul, Minnesota.

#SimilarOrganizations #People #Website #More

SQUAREX

Social Links:

Industry:
Health Care Medical Pharmaceutical Wellness

Founded:
2012-01-01

Address:
Saint Paul, Minnesota, United States

Country:
United States

Website Url:
http://www.squarex-pharma.com

Total Employee:
1+

Status:
Active

Email Addresses:
[email protected]

Technology used in webpage:
Euro Cloudflare Hosting


Similar Organizations

abfero-pharmaceuticals-logo

Abfero Pharmaceuticals

Abfero Pharmaceuticals is a clinical stage pharmaceutical company that specializes in healthcare and medical industry.

aerie-pharmaceuticals-logo

Aerie Pharmaceuticals

Aerie Pharmaceuticals is a clinical-stage pharmaceutical company developing products for the treatment of glaucoma.

aerogen-pharma-logo

AEROGEN PHARMA

AEROGEN PHARMA is a clinical-stage specialty pharmaceutical company developing proprietary inhaled medications.

affinivax-logo

Affinivax

Affinivax is a biopharmaceutical company developing vaccines that target infectious diseases.

karyopharm-therapeutics-logo

Karyopharm Therapeutics

Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for the treatment of cancer and other major diseases.

metacrine-logo

Metacrine

Metacrine is a clinical-stage bio pharmaceutical company focused on building an innovative pipeline of best-in-class drugs.

perosphere-logo

Perosphere

Perosphere is a private specialty pharmaceutical company developing rescue medications.

Current Employees Featured

hugh-mctavish_image

Hugh McTavish
Hugh McTavish Co-Founder & President @ Squarex
Co-Founder & President

thomas-d-horn_image

Thomas D. Horn
Thomas D. Horn Co-Founder @ Squarex
Co-Founder

Founder


hugh-mctavish_image

Hugh McTavish

thomas-d-horn_image

Thomas D. Horn

Official Site Inspections

http://www.squarex-pharma.com

  • Host name: 35.0.153.160.host.secureserver.net
  • IP address: 160.153.0.35
  • Location: Scottsdale United States
  • Latitude: 33.6013
  • Longitude: -111.8867
  • Metro Code: 753
  • Timezone: America/Phoenix
  • Postal: 85260

Loading ...

More informations about "Squarex"

Squarex - Crunchbase Company Profile & Funding

Contact Email [email protected] Squarex is a clinical-stage pharmaceutical company developing a drug and topical application to prevent infections. This application develops a โ€ฆSee details»

Improving immune system to prevent cold sores. Return - Squarex

Maybe the Only Opportunity in Pharma With: 1. Statistically Significant Efficacy in 3 of 3 clinical trials โ€ข Phase 1, Phase 2, and Mechanism of Action clinical trials completed, all with significant โ€ฆSee details»

Squarex Company Profile 2024: Valuation, Funding

Www.squarex-pharma.com. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. 1000 Westgate Drive; Suite 1010; Saint Paul, MN 55114; United StatesSee details»

SquareX Pharmaceutical Corporation - LinkedIn

SquareX Pharmaceutical Corporation Pharmaceutical Manufacturing St Paul, Minnesota 109 followers We are developing a drug (topical immune stimulator) that prevents oral herpes or โ€ฆSee details»

Squarex Announces End of Phase 2 Meeting with FDA โ€ฆ

Saint Paul, Minnesota, USA, 19 January 2021 โ€“ Squarex Pharma (SQX), a St. Paul, Minnesota, USA-based company, announced updated results from its Phase 2 clinical study on humans with its novel asset SQX770 for prevention โ€ฆSee details»

Squarex, LLC: Preventing oral herpes with a topical โ€ฆ

Squarex would be an attractive acquisition or licensing opportunity for large pharmaceutical companies, both pre-and post-approval and revenue of the Squarex lead drug. Partnering Squarex may partner with an established โ€ฆSee details»

SquareX Overview

[email protected] Pre-IPO Stock O๏ฌ€ering Potential 100x Return www.squarex-pharma.com SquareX Overview $22 million pre-money valuation. $3.00 per share, Estimated โ€ฆSee details»

St. Paul-based Squarex Withdraws IPO Plans - Twin โ€ฆ

May 22, 2023 A St. Paul biotech company run by one-time gubernatorial candidate Hugh McTavish has shelved plans to go public, for now. On Friday, Squarex Pharmaceuticals Corp. submitted paperwork asking the U ...See details»

Squarex Pharmaceutical Seeks IPO For Development โ€ฆ

Jan 23, 2023 Squarex Pharmaceutical Corporation has filed to raise $17.8 million in an IPO of its common stock, according to an S-1 registration statement. The firm is a biopharma developing a treatment for ...See details»

Squarex Announces End of Phase 2 Meeting with FDA for its Cold โ€ฆ

Jan 19, 2021 Squarex announces that is has completed an End-of-Phase 2 meeting with the U.S. FDA which has provided a clear and achievable path to a New Drug Application in the โ€ฆSee details»

Cold sore prevention biotech Squarex withdraws $15 million IPO

May 19, 2023 Squarex's primary candidate, SQX770, was able to cut the number of cold sore outbreaks by 2.6-fold in the period from 42 to 120 days after a single topical dose on the arm โ€ฆSee details»

Squarex Pharma Signs Investment Term Sheet for Up to $75

Dec 7, 2021 Joseph Cunningham, CFO, Squarex Pharma Tel 612 787-7281 [email protected]. Joseph Cunningham Squarex Pharma +1 612-787-7281 โ€ฆSee details»

SciMed Biotech Podcast with Hugh McTavish of SquareX โ€ฆ

Sep 19, 2024 As the founder and CEO of SquareX Pharmaceutical Corporation and IGF Oncology, Hugh shares his unique journey from facing personal health challenges to โ€ฆSee details»

Squarex | Saint Louis Park MN - Facebook

Squarex, Birchwood. 21 likes. We are a clinical stage pharmaceutical company developing a topical formulation of the immunomodulator squaric acid dibutyl ester for prevention of recurrent cold sores...See details»

Squarex Announces Positive Results from Completed Phase 2 โ€ฆ

ST. PAUL, Minn., Aug. 5, 2019 /PRNewswire/ -- Squarex, a clinical-stage pharmaceutical company developing a topical immunomodulator for the long-term prevention of recurrent cold โ€ฆSee details»

Squarex Announces End of Phase 2 Meeting with FDA for its Cold โ€ฆ

About Squarex Pharma Squarex is a clinical stage pharmaceutical company which has developed a topical formulation of the immunomodulator squaric acid dibutyl ester for the prevention of โ€ฆSee details»

Squarex Announces Publication of Clinical Results for SQX770 for โ€ฆ

Feb 14, 2019 Squarex is a clinical-stage pharmaceutical company developing a topical formulation of the immunomodulator squaric acid dibutyl ester (SQX770) for the prevention of โ€ฆSee details»

Cold sore prevention biotech Squarex Pharmaceutical files for a โ€ฆ

Jan 17, 2023 Squarex Pharmaceutical, a Phase 2 biotech developing a topical therapy for cold sores, filed on Tuesday with the SEC to raise up to $15 million in an initial public offering. In its โ€ฆSee details»

A phase 2, multicenter, placebo-controlled study of single

Electronic address: [email protected]. PMID: 32289388 DOI: 10.1016/j.jaad.2020.04.021 No abstract available. Publication types Clinical Trial, Phase II โ€ฆSee details»

linkstock.net © 2022. All rights reserved